If the primary outcome for PoC is demonstrated for the low cells/ dose and the selected cells/dose then participants in the untreated control group who completed the 26 week visit, continue to meet the eligibility criteria and are suitable for immunosuppression therapy are allowed to cross over to treatment with ASP7317.